The Economist asks:
Will the US FDA approve a drug used to reverse the effects of Alzheimer's disease on the brain and/or approve a vaccine to prevent Alzheimer's disease as of 2035?
Alzheimer's disease accounts for 60-80% of dementia cases (Alzheimer's Association). The outcome will be determined using available FDA approval data available as of 31 December 2035. "Expanded access/compassionate use," "accelerated approval," and "emergency use" authorizations would not count (FDA - Expanded Access, FDA - Accelerated Approval, FDA - Emergency Use Authorization).